WuXi STA Breaks Ground on New Pharma Manufacturing Site in Delaware


Site expected to boost the CDMO’s global drug production capabilities

WuXi STA—a subsidiary of WuXi AppTec and a contract development and manufacturing organization (CDMO) serving the life sciences industry—has broken ground on its new 190-acre pharmaceutical manufacturing campus in Middletown, DE. First announced in June 2021, this site will be the CDMO’s second facility in the US, providing additional capacity and flexibility to meet customer needs.

The new state-of-the-art facility is expected to begin operations by 2025, and will create approximately 500 full-time jobs by 2026. Phase I of the new campus will provide formulation development, clinical, and commercial drug product manufacturing services for various oral and injectable dosage forms, along with packaging, labeling, storage, and distribution services for clinical trial materials and commercial drug products. The aforementioned site is also expected to further enhance the company's global drug production capacity and capabilities.

"I would like to thank our federal, state, and local partners in Delaware for their continued support in the establishment of this site," says Minzhang Chen, PhD, co-CEO of WuXi AppTec and CEO of WuXi STA. "WuXi STA continues to increase our capabilities and capacities to better serve our customers through a more robust and reliable supply chain. … We look forward to working with our customers to swiftly deliver their innovative therapies to market in order to save lives and improve healthcare for patients."

Related Videos
© 2024 MJH Life Sciences

All rights reserved.